Latest News

Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflam...

Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammator

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in ...

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Child

Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 3...

Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 20

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Compa...

Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's

Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United...

Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United Stat

Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Re...

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release

Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024

Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024

Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a On...

Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pil

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook

Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749...

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (ola

Teva to Present at the 2024 Bank of America Healthcare Conference

Teva to Present at the 2024 Bank of America Healthcare Conference